Neurocrine Biosciences Files 8-K on Financials
Ticker: NBIX · Form: 8-K · Filed: 2025-02-06T00:00:00.000Z
Sentiment: neutral
Topics: financial-reporting, operations
Related Tickers: NBIX
TL;DR
NBIX filed an 8-K detailing financial results and operations.
AI Summary
Neurocrine Biosciences, Inc. filed an 8-K on February 6, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, indicating a regular update on the company's financial performance and operational status. The company is incorporated in Delaware and headquartered in San Diego, California.
Why It Matters
This filing provides investors with crucial updates on Neurocrine Biosciences' financial health and operational performance, enabling informed investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not appear to contain any new or significant risk-related information.
Key Players & Entities
- NEUROCRINE BIOSCIENCES, INC. (company) — Registrant
- February 6, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- San Diego, CA (location) — Principal executive offices
- 0-22705 (filing_id) — Commission File Number
FAQ
What specific financial information is being reported in this 8-K filing?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits', suggesting a comprehensive financial update.
When was the earliest event reported in this filing?
The earliest event reported is dated February 6, 2025.
Where is Neurocrine Biosciences, Inc. incorporated?
Neurocrine Biosciences, Inc. is incorporated in Delaware.
What is the principal executive office address for Neurocrine Biosciences, Inc.?
The principal executive offices are located at 6027 Edgewood Bend Court, San Diego, CA 92130.
What is the Commission File Number for Neurocrine Biosciences, Inc.?
The Commission File Number for Neurocrine Biosciences, Inc. is 0-22705.
Filing Stats: 508 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2025-02-06 16:04:44
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value NBIX Nasdaq Global Select Mar
Filing Documents
- nbix-20250206.htm (8-K) — 23KB
- q4-2024xearningsrelease.htm (EX-99.1) — 219KB
- nbix-20250206_g1.jpg (GRAPHIC) — 18KB
- 0000914475-25-000034.txt ( ) — 429KB
- nbix-20250206.xsd (EX-101.SCH) — 2KB
- nbix-20250206_lab.xml (EX-101.LAB) — 21KB
- nbix-20250206_pre.xml (EX-101.PRE) — 12KB
- nbix-20250206_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On February 6, 2025, Neurocrine Biosciences, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2024. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. Exhibit Description 99.1 Press Release dated February 6, 2025 104 Cover Page Interactive Data File
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUROCRINE BIOSCIENCES, INC. Dated: February 6, 2025 /s/ Matthew C. Abernethy Matthew C. Abernethy Chief Financial Officer (Duly authorized officer and Principle Financial Officer)